TSHA · Taysha Gene Therapies Inc. Common Stock
View on chartInsiders & Stakes
| Session R.A. II President and CEO | ▼ Sell | Open Market | 8,871,747 Shares held | 7/13/2023 | View profile |
| Sean P. Nolan Director | ▼ Sell | Open Market | 2,908,257 Shares held | 1/26/2026 | View profile |
| Paul B. Manning Director | ▲ Buy | Open Market | 2,841,704 Shares held | 5/30/2025 | View profile |
| Alam Kamran Chief Financial Officer | ▼ Sell | Open Market | 1,442,131 Shares held | 2/4/2026 | View profile |
| John A. Stalfort III Director | ▲ Buy | Grant | 1,176,559 Shares held | 6/1/2026 | View profile |
| Nagendran Sukumar Director | ▼ Sell | Open Market | 936,410 Shares held | 7/10/2026 | View profile |
| PRASAD SUYASH CMO and Head of R&D | ▼ Sell | Open Market | 530,589 Shares held | 7/6/2022 | View profile |
| Donenberg Phillip B. Director | ▲ Buy | Grant | 241,289 Shares held | 6/1/2026 | View profile |
| Sepp-Lorenzino Laura EVP, Chief Scientific Officer | ▲ Buy | Grant | 127,178 Shares held | 6/1/2026 | View profile |
| Long Alison S | ▲ Buy | Grant | 127,178 Shares held | 6/1/2026 | View profile |
Transaction History
| Nagendran Sukumar | ▼ Sell | Open Market | 200,000 | $1.2M | 7/10/2026 |
| Donenberg Phillip B. | ▲ Buy | Grant | 21,335 | $0 | 6/1/2026 |
| Long Alison S | ▲ Buy | Grant | 21,335 | $0 | 6/1/2026 |
| Sepp-Lorenzino Laura | ▲ Buy | Grant | 21,335 | $0 | 6/1/2026 |
| John A. Stalfort III | ▲ Buy | Grant | 21,335 | $0 | 6/1/2026 |
| Nagendran Sukumar | ▲ Buy | Option Exercise | 19,021 | $33K | 4/10/2026 |
| Nagendran Sukumar | ▼ Sell | Open Market | 200,000 | $892K | 4/10/2026 |
| Alam Kamran | ▼ Sell | Open Market | 1,655 | $7K | 2/4/2026 |
| Alam Kamran | ▼ Sell | Open Market | 23,849 | $110K | 1/26/2026 |
| Nagendran Sukumar | ▼ Sell | Open Market | 26,918 | $124K | 1/26/2026 |
| Sean P. Nolan | ▼ Sell | Open Market | 41,312 | $190K | 1/26/2026 |
| Nagendran Sukumar | ▼ Sell | Open Market | 89,132 | $423K | 1/23/2026 |
| Sean P. Nolan | ▼ Sell | Open Market | 136,789 | $650K | 1/23/2026 |
| Alam Kamran | ▼ Sell | Open Market | 78,968 | $375K | 1/23/2026 |
| Nagendran Sukumar | ▲ Buy | Option Exercise | 111,324 | $78K | 1/12/2026 |
| Nagendran Sukumar | ▲ Buy | Option Exercise | 88,676 | $152K | 1/12/2026 |
| Nagendran Sukumar | ▼ Sell | Open Market | 200,000 | $942K | 1/12/2026 |
| Nagendran Sukumar | ▲ Buy | Grant | 427,000 | $0 | 1/12/2026 |
| Sean P. Nolan | ▲ Buy | Grant | 1,008,000 | $0 | 1/12/2026 |
| Alam Kamran | ▲ Buy | Grant | 359,000 | $0 | 1/12/2026 |
| Nagendran Sukumar | ▲ Buy | Option Exercise | 260,047 | $445K | 12/1/2025 |
| Nagendran Sukumar | ▼ Sell | Open Market | 260,047 | $1.2M | 12/1/2025 |
| Nagendran Sukumar | ▲ Buy | Option Exercise | 70,172 | $49K | 11/28/2025 |
| Nagendran Sukumar | ▲ Buy | Option Exercise | 39,953 | $68K | 11/28/2025 |
| Nagendran Sukumar | ▼ Sell | Open Market | 110,125 | $523K | 11/28/2025 |
| Nagendran Sukumar | ▲ Buy | Option Exercise | 41,150 | $29K | 9/10/2025 |
| Nagendran Sukumar | ▼ Sell | Open Market | 200,000 | $646K | 9/10/2025 |
| Nagendran Sukumar | ▼ Sell | Open Market | 57,054 | $163K | 8/21/2025 |
| Alam Kamran | ▼ Sell | Open Market | 54,491 | $155K | 8/21/2025 |
| Sepp-Lorenzino Laura | ▲ Buy | Grant | 56,623 | $0 | 6/2/2025 |
| Donenberg Phillip B. | ▲ Buy | Grant | 56,623 | $0 | 6/2/2025 |
| Long Alison S | ▲ Buy | Grant | 56,623 | $0 | 6/2/2025 |
| John A. Stalfort III | ▲ Buy | Grant | 56,623 | $0 | 6/2/2025 |
| Paul B. Manning | ▲ Buy | Open Market | 750,000 | $2.1M | 5/30/2025 |
| Alam Kamran | ▼ Sell | Tax Withholding | 29,843 | $50K | 3/11/2025 |
| Nagendran Sukumar | ▲ Buy | Grant | 324,500 | $0 | 1/2/2025 |
| Sean P. Nolan | ▲ Buy | Grant | 892,500 | $0 | 1/2/2025 |
| Alam Kamran | ▲ Buy | Grant | 431,000 | $0 | 1/2/2025 |
| Paul B. Manning | ▲ Buy | Open Market | 1,333,333 | $3.0M | 6/27/2024 |
| John A. Stalfort III | ▲ Buy | Grant | 49,220 | $0 | 5/29/2024 |
| Long Alison S | ▲ Buy | Grant | 49,220 | $0 | 5/29/2024 |
| Donenberg Phillip B. | ▲ Buy | Grant | 49,220 | $0 | 5/29/2024 |
| Sepp-Lorenzino Laura | ▲ Buy | Grant | 49,220 | $0 | 5/29/2024 |
| Alam Kamran | ▼ Sell | Tax Withholding | 1,288 | $2K | 2/2/2024 |
| Alam Kamran | ▲ Buy | Grant | 590,413 | $0 | 1/2/2024 |
| Nagendran Sukumar | ▲ Buy | Grant | 863,617 | $0 | 1/2/2024 |
| Sean P. Nolan | ▲ Buy | Grant | 1,184,688 | $0 | 1/2/2024 |
| Paul B. Manning | ▲ Buy | Open Market | 100,000 | $163K | 11/17/2023 |
| Alam Kamran | ▼ Sell | Open Market | 33,000 | $77K | 8/24/2023 |
| Paul B. Manning | ▲ Buy | Open Market | 16,466,667 | $14.8M | 8/16/2023 |
| John A. Stalfort III | ▲ Buy | Open Market | 388,889 | $350K | 8/16/2023 |
| John A. Stalfort III | ▲ Buy | Open Market | 388,889 | $350K | 8/16/2023 |
| Sean P. Nolan | ▲ Buy | Open Market | 444,444 | $400K | 8/16/2023 |
| Donenberg Phillip B. | ▲ Buy | Open Market | 111,111 | $100K | 8/16/2023 |
| John A. Stalfort III | ▼ Sell | Gift | 50,000 | $0 | 8/16/2023 |
| Session R.A. II | ▼ Sell | Open Market | 5,344 | $4K | 7/13/2023 |
| Session R.A. II | ▼ Sell | Open Market | 80,528 | $57K | 7/12/2023 |
| Session R.A. II | ▼ Sell | Open Market | 18,100 | $13K | 6/23/2023 |
| Session R.A. II | ▼ Sell | Open Market | 10,508 | $7K | 6/22/2023 |
| Session R.A. II | ▼ Sell | Open Market | 138,962 | $98K | 6/21/2023 |
| Session R.A. II | ▼ Sell | Open Market | 295,653 | $210K | 6/20/2023 |
| Alam Kamran | ▲ Buy | Grant | 6,230 | — | 5/31/2023 |
| Nagendran Sukumar | ▲ Buy | Open Market | 5,000 | $3K | 5/16/2023 |
| Session R.A. II | ▼ Sell | Other | 251,296 | $0 | 3/6/2023 |
| Alam Kamran | ▲ Buy | Grant | 18,691 | — | 2/2/2023 |
| Paul B. Manning | ▲ Buy | Open Market | 1,500,000 | $3.0M | 10/31/2022 |
| Alam Kamran | ▼ Sell | Open Market | 3,325 | $12K | 8/23/2022 |
| Alam Kamran | ▼ Sell | Open Market | 9,717 | $34K | 8/22/2022 |
| Alam Kamran | ▼ Sell | Open Market | 11,482 | $43K | 8/19/2022 |
| Alam Kamran | ▼ Sell | Open Market | 7,476 | $29K | 8/18/2022 |
| PRASAD SUYASH | ▼ Sell | Open Market | 8,956 | $34K | 7/6/2022 |
| PRASAD SUYASH | ▼ Sell | Open Market | 3,905 | $14K | 7/5/2022 |
| PRASAD SUYASH | ▼ Sell | Open Market | 23,923 | $84K | 7/1/2022 |
| PRASAD SUYASH | ▼ Sell | Open Market | 13,892 | $52K | 6/30/2022 |
| PRASAD SUYASH | ▼ Sell | Open Market | 12,324 | $47K | 6/29/2022 |
| Paul B. Manning | ▲ Buy | Open Market | 50,000 | $392K | 2/3/2022 |
| Paul B. Manning | ▲ Buy | Open Market | 26,602 | $209K | 2/3/2022 |
| Paul B. Manning | ▲ Buy | Open Market | 58,000 | $451K | 2/2/2022 |
| Paul B. Manning | ▲ Buy | Open Market | 45,000 | $350K | 2/2/2022 |
| Paul B. Manning | ▲ Buy | Open Market | 22,000 | $171K | 2/2/2022 |
| Nagendran Sukumar | ▲ Buy | Open Market | 10,000 | $80K | 2/2/2022 |
| Donenberg Phillip B. | ▲ Buy | Open Market | 3,000 | $23K | 2/2/2022 |
| Paul B. Manning | ▲ Buy | Open Market | 2,202 | $29K | 11/24/2021 |
| Session R.A. II | ▲ Buy | Open Market | 16,510 | $200K | 11/23/2021 |
| Paul B. Manning | ▲ Buy | Open Market | 20,000 | $251K | 11/23/2021 |
| Session R.A. II | ▲ Buy | Open Market | 26,008 | $329K | 11/23/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
TSHA Valuation Debate Highlights Split Views
Recent articles discuss conflicting views on Taysha Gene Therapies' valuation, with some suggesting the stock is above fair value based on book value, while others argue it may be undervalued. This debate occurs while the stock trades near its 52-week low, reflecting significant uncertainty among investors regarding the company's true worth.
TSHA Valuation Debate Highlights Split Views. Recent articles discuss conflicting views on Taysha Gene Therapies' valuation, with some suggesting the stock is above fair value based on book value, while others argue it may be undervalued. This debate occurs while the stock trades near its 52-week low, reflecting significant uncertainty among investors regarding the company's true worth.